Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
- 1 November 2022
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 113 (Pt A) , 109365
Abstract
No abstract availableKeywords
This publication has 214 references indexed in Scilit:
- Chemoimmunotherapy: reengineering tumor immunityCancer Immunology, Immunotherapy, 2013
- CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current StatusCurrent Oncology Reports, 2011
- Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial dataCancer Treatment Reviews, 2010
- A Renaissance of Elicitors: Perception of Microbe-Associated Molecular Patterns and Danger Signals by Pattern-Recognition ReceptorsAnnual Review of Plant Biology, 2009
- PD‐1 signaling in primary T cellsImmunological Reviews, 2009
- BevacizumabDrugs, 2008
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002